| 臺大學術典藏 |
2020-04-28T07:12:31Z |
Hierarchical sensor network architecture for stationary smart node supervision
|
Jin, M.-H.; Wu, W.-J.; Chen, C.-K.; Chen, Y.-F.; Wen, C.-M.; Kao, C.-Y.; Yu, S.-A.; Lin, Y.-H.; Huang, J.-G.; Rao, H.; Hsu, C.-H.; Lee, C.-K.; CHIH-KUNG LEE |
| 臺大學術典藏 |
2020-04-27T08:45:29Z |
The application of aquaplast thermoplastic as a bolus material in the radiotherapy of a patient with classic Kaposi's sarcoma at the lower extremity
|
Hsu C.-H.; Jeng S.-C.; Ting L.-L.; CHIA-HSIEN CHENG; Huang W.-T.; Huang K.-M.; Huang K.-M.;Hsu C.-H.;Jeng S.-C.;Ting L.-L.;Chia-Hsien Cheng;Huang W.-T. |
| 臺大學術典藏 |
2020-04-27T08:45:15Z |
Serum transforming growth factor-β1 change after neoadjuvant chemoradiation therapy is associated with postoperative pulmonary complications in esophageal cancer patients undergoing combined modality therapy
|
Lu S.-L.;Hsu F.-M.;Tsai C.-L.;Wu J.-K.;Lee J.-M.;Huang P.-M.;Hsu C.-H.;Koong A.C.;Chang D.T.;Chia-Hsien Cheng; Lu S.-L.; Hsu F.-M.; Tsai C.-L.; Wu J.-K.; Lee J.-M.; Huang P.-M.; Hsu C.-H.; Koong A.C.; Chang D.T.; CHIA-HSIEN CHENG |
| 臺大學術典藏 |
2020-04-27T08:45:09Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.;Chia-Hsien Cheng;Huang C.-Y.;Tsai Y.-C.;Lin C.-C.;Hsu C.-H.;Cheng A.-L.;Pu Y.-S.; Chiang Y.; CHIA-HSIEN CHENG; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C.;Lin C.-C.;Huang T.-C.;Huang P.-M.;Kuo H.-Y.;Chang C.-H.;Wang C.-C.;Chia-Hsien Cheng;Yeh K.-H.;Hsu C.-H.;Lee J.-M.; Guo J.-C.; Lin C.-C.; Huang T.-C.; Huang P.-M.; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; CHIA-HSIEN CHENG; Yeh K.-H.; Hsu C.-H.; Lee J.-M. |
| 臺大學術典藏 |
2020-04-27T08:45:05Z |
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment
|
Lu S.-L.;Hsu F.-M.;Tsai C.-L.;Lee J.-M.;Huang P.-M.;Hsu C.-H.;Lin C.-C.;Chang Y.-L.;Hsieh M.-S.;Chia-Hsien Cheng; Lu S.-L.; Hsu F.-M.; Tsai C.-L.; Lee J.-M.; Huang P.-M.; Hsu C.-H.; Lin C.-C.; Chang Y.-L.; Hsieh M.-S.; CHIA-HSIEN CHENG |
| 臺大學術典藏 |
2020-04-24T08:53:16Z |
Growth and characterization of CdSe nanoneedles and other one-dimensional CdSe nanostructures
|
Cheng, J.H.; Chao, H.Y.; Chang, Y.H.; Hsu, C.H.; Cheng, C.L.; Chen, T.T.; Chen, Y.F.; Chu, M.W. |
| 臺大學術典藏 |
2020-04-24T08:53:13Z |
Growth and characterization of oriented CdSe nanobelts and nanorods
|
Cheng, J.H.; Chao, H.Y.; Chang, Y.H.; Hsu, C.H.; Cheng, C.L.; Chu, M.-W.; Chen, Y.F. |
| 臺大學術典藏 |
2020-04-21T03:52:07Z |
Enhancement of thermoelectric figure of merit in β -Zn4Sb3 by indium doping control
|
Chen, Y. Y.; Wei, P. C.; Yang, C. C.; Chen, J. L.; Sankar, R.; Chen, C. L.; Hsu, C. H.; Chang, C. C.; Chen, C. L.; Dong, C. L.; Chou, F. C.; Chen, K. H.; Wu, M. K. |
| 臺大學術典藏 |
2020-04-16T02:35:00Z |
Mobile nursing cart with software defined radio for healthcare enterprises
|
Hsu, C.-H.;Hsieh, S.-H.;Hsu, J.-T.;Cheng, P.-H.;Chen, S.-J.;Lai, F.-P.; Hsu, C.-H.; Hsieh, S.-H.; Hsu, J.-T.; Cheng, P.-H.; Chen, S.-J.; Lai, F.-P.; FEI-PEI LAI |
| 臺大學術典藏 |
2020-04-16T02:35:00Z |
Ubiquitous mobile personal health system based on cloud computing
|
Hsu, J.-T.; Hsieh, S.-H.; Lo, C.-C.; Hsu, C.-H.; Cheng, P.-H.; Chen, S.-J.; Lai, F.-P.; FEI-PEI LAI; Hsu, J.-T.;Hsieh, S.-H.;Lo, C.-C.;Hsu, C.-H.;Cheng, P.-H.;Chen, S.-J.;Lai, F.-P. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Chen L.-T.; Shiah H.-S.;Cheng A.-L.;Chiun Hsu;Hsu C.-H.;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Chiun Hsu; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Yang C.-H.; Cheng A.-L.; Lin C.-C.;Chiun Hsu;Hsu C.-H.;Hsu W.-L.;Cheng A.-L.;Yang C.-H.; Lin C.-C.; Chiun Hsu; Hsu C.-H.; Hsu W.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:24Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Yang C.-H.; Chiun Hsu; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Lin C.-C.; Lin C.-C.;Yeh K.-H.;Yang C.-H.;Chiun Hsu;Tsai Y.-C.;Hsu W.-L.;Cheng A.-L.;Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:23Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Yang C.-H.; Yang P.-C.; Cheng A.-L.; Lin C.-C.; Hsu C.-H.; Yu C.-J.; Chang Y.-C.; Chiun Hsu; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; Chiun Hsu; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Kuo S.-H.;Chiun Hsu;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Chiun Hsu; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:20Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:19Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:17Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.;Lin Z.-Z.;Chiun Hsu;Shen Y.-C.;Hsu C.-H.;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:16Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Chiun Hsu ;Shen Y.-C. ;Hsu C.-H. ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:16Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-H.; Hu F.-C.; Hsu C.-Y. ;Shen Y.-C. ;Yu C.-W. ;Chiun Hsu ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Chiun Hsu; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Chiun Hsu; Hsu C.-H.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y. |
